Effects of SGLT-2 Inhibitors and Visceral Fat on Glucose Metabolism

Simple item page
dc.contributor.otherBleiberg, Benen
dc.contributor.otherAyers, Colby R.en
dc.contributor.otherMallory, Craig R.en
dc.contributor.otherJin, Eunsook S.en
dc.contributor.otherNeeland, Ian J.en
dc.creatorHughes, Connoren
dc.date.accessioned2018-06-06T23:48:24Z
dc.date.available2018-06-06T23:48:24Z
dc.date.issued2018-01-23
dc.descriptionThe 56th Annual Medical Student Research Forum at UT Southwestern Medical Center (Tuesday, January 23, 2018, 2-5 p.m., D1.600)en
dc.description.abstractINTRODUCTION: Abdominal obesity and excess visceral adiposity (VAT), have strong associations with insulin resistance, hyperglycemia and type 2 diabetes. A previous pilot study showed that participants with high VAT have less 13C enrichment in glucose reflecting an abundant endogenous substrate pool from adipose turnover for gluconeogenesis, compared with participants with low VAT. This study aims to evaluate the effects of a SGLT-2 inhibitor known to modify markers of VAT on gluconeogenic pathways in the liver. METHODS: Obese adults without diabetes were stratified into high and low VAT groups based on MRI (high n=8, low n=7). After an overnight fast, participants were administered non-radioactive labeled glycerol, and blood samples were collected to calculate glycerol enrichment at sequential time points over 180 minutes. Participants were then randomized to receive empagliflozin 10 mg daily or matching placebo for 3 months and glycerol studies were repeated. RESULTS: High VAT subjects demonstrated a significantly lower enrichment of ingested glycerol in blood glucose, when compared to low VAT individuals for the 60-180 minute interval (p <0.001). During this same time interval, pentose phosphate pathway activity was significantly decreased in high VAT, compared to low VAT subjects (p<0.01). The effects of empagliflozin on these pathways are currently being analyzed. DISCUSSION: SGLT-2 inhibitors inhibit renal glucose reabsorption in the proximal nephron, inducing weight loss and decreasing systolic blood pressure. This medication has been suggested to reduce CVD event rate and lower hemoglobinA1c levels up to 1%. Observed differences in pathways between high visceral fat subjects on a SGLT-2 inhibitor compared to control high visceral fat subjects could provide insight into the physiologic changes provided by SGLT-2 inhibitors.en
dc.description.sponsorshipSouthwestern Medical Foundationen
dc.identifier.citationHughes, C, Bleiberg, B., Ayers, C. R., Malloy, C. R., Jin, E. S., & Neeland, I. J. (2018, January 23). Effects of SGLT-2 inhibitors and visceral fat on glucose metabolism. Poster session presented at the 56th Annual Medical Student Research Forum, Dallas, TX. Retrieved from https://hdl.handle.net/2152.5/5343en
dc.identifier.urihttps://hdl.handle.net/2152.5/5343
dc.language.isoenen
dc.relation.ispartofseries56th Annual Medical Student Research Forumen
dc.subjectClinical Researchen
dc.subject.meshAdipose Tissueen
dc.subject.meshGluconeogenesisen
dc.subject.meshGlycerolen
dc.subject.meshIntra-Abdominal Faten
dc.subject.meshObesityen
dc.titleEffects of SGLT-2 Inhibitors and Visceral Fat on Glucose Metabolismen
dc.title.alternativeEffects of SGLT-2 Inhibitors on Visceral Fat and Glucose Metabolismen
dc.typePresentationen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Hughes, C.pdf
Size:
1.43 MB
Format:
Adobe Portable Document Format
Description:
PDF file -- public access
Download

Collections

Annual Medical Student Research Forum